{"entity":{"id":"nct06229041","kind":"trial","name":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)","aka":[],"tldr":"A phase 3 trial in colorectal cancer, run by Peking University Cancer Hospital & Institute, now recruiting.","summary":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) is a phase 3, randomised interventional study registered as NCT06229041 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 472 participants, started 2023-03-29 and due to reach its primary completion in 2027-10-01. Interventions recorded: Camrelizumab ＋Immunotherapy. Conditions listed: Rectal Cancer. Primary outcome: The PCR rate between total neoadjuvant treatment ±immunotherapy. Colorectal eligibility wording from the registry: \"colorectal adenocarcinoma confirmed by pathology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06229041","url":"https://clinicaltrials.gov/study/NCT06229041"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06229041","phase":"3","setting":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)","sponsor":"Peking University Cancer Hospital & Institute","enrolled":472,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06229041/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}